{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T09:47:03Z","timestamp":1769507223331,"version":"3.49.0"},"reference-count":65,"publisher":"Impact Journals, LLC","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncotarget"],"published-print":{"date-parts":[[2017,1,3]]},"DOI":"10.18632\/oncotarget.13439","type":"journal-article","created":{"date-parts":[[2016,11,18]],"date-time":"2016-11-18T17:27:20Z","timestamp":1479490040000},"page":"418-429","source":"Crossref","is-referenced-by-count":11,"title":["Immunological effects of nilotinib prophylaxis after allogeneic stem cell transplantation in patients with advanced chronic myeloid leukemia or philadelphia chromosome-positive acute lymphoblastic leukemia"],"prefix":"10.18632","volume":"8","author":[{"given":"Nira","family":"Varda-Bloom","sequence":"first","affiliation":[{"name":"Sheba Medical Center, Ramat-Gan, Israel"},{"name":"Sackler Faculty of Medicine, Tel-Aviv University, Israel"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ivetta","family":"Danylesko","sequence":"additional","affiliation":[{"name":"Sheba Medical Center, Ramat-Gan, Israel"},{"name":"Sackler Faculty of Medicine, Tel-Aviv University, Israel"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roni","family":"Shouval","sequence":"additional","affiliation":[{"name":"Sheba Medical Center, Ramat-Gan, Israel"},{"name":"Sackler Faculty of Medicine, Tel-Aviv University, Israel"},{"name":"Dr. Pinchas Bornstein Talpiot Medical Leadership Program, Sheba Medical Center, Israel"},{"name":"Bar-Ilan University, Ramat Gan, Israel"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shiran","family":"Eldror","sequence":"additional","affiliation":[{"name":"Sheba Medical Center, Ramat-Gan, Israel"},{"name":"Sackler Faculty of Medicine, Tel-Aviv University, Israel"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atar","family":"Lev","sequence":"additional","affiliation":[{"name":"Sheba Medical Center, Ramat-Gan, Israel"},{"name":"Sackler Faculty of Medicine, Tel-Aviv University, Israel"},{"name":"Pediatric Immunology Service, Jeffrey Modell Foundation, USA"},{"name":"Edmond and Lily Safra Children's Hospital, Israel"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacqueline","family":"Davidson","sequence":"additional","affiliation":[{"name":"Sheba Medical Center, Ramat-Gan, Israel"},{"name":"Sackler Faculty of Medicine, Tel-Aviv University, Israel"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Esther","family":"Rosenthal","sequence":"additional","affiliation":[{"name":"Sheba Medical Center, Ramat-Gan, Israel"},{"name":"Sackler Faculty of Medicine, Tel-Aviv University, Israel"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yulia","family":"Volchek","sequence":"additional","affiliation":[{"name":"Sheba Medical Center, Ramat-Gan, Israel"},{"name":"Sackler Faculty of Medicine, Tel-Aviv University, Israel"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noga","family":"Shem-Tov","sequence":"additional","affiliation":[{"name":"Sheba Medical Center, Ramat-Gan, Israel"},{"name":"Sackler Faculty of Medicine, Tel-Aviv University, Israel"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ronit","family":"Yerushalmi","sequence":"additional","affiliation":[{"name":"Sheba Medical Center, Ramat-Gan, Israel"},{"name":"Sackler Faculty of Medicine, Tel-Aviv University, Israel"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Avichai","family":"Shimoni","sequence":"additional","affiliation":[{"name":"Sheba Medical Center, Ramat-Gan, Israel"},{"name":"Sackler Faculty of Medicine, Tel-Aviv University, Israel"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raz","family":"Somech","sequence":"additional","affiliation":[{"name":"Sheba Medical Center, Ramat-Gan, Israel"},{"name":"Sackler Faculty of Medicine, Tel-Aviv University, Israel"},{"name":"Pediatric Immunology Service, Jeffrey Modell Foundation, USA"},{"name":"Edmond and Lily Safra Children's Hospital, Israel"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arnon","family":"Nagler","sequence":"additional","affiliation":[{"name":"Sheba Medical Center, Ramat-Gan, Israel"},{"name":"Sackler Faculty of Medicine, Tel-Aviv University, Israel"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"7892","published-online":{"date-parts":[[2016,11,18]]},"reference":[{"key":"1","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1182\/blood-2013-05-501569","article-title":"European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013","volume":"122","author":"Kantarjian","year":"2013","journal-title":"Blood"},{"key":"2","doi-asserted-by":"crossref","first-page":"21","DOI":"10.3109\/10428194.2012.708753","article-title":"Optimal approach to treatment of patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: how to best use all the available tools","volume":"54","author":"Ribera","year":"2013","journal-title":"Leuk Lymphoma"},{"key":"3","doi-asserted-by":"crossref","first-page":"2828","DOI":"10.1182\/blood-2007-04-038943","article-title":"How I treat chronic myeloid leukemia in the imatinib era","volume":"110","author":"Goldman","year":"2007","journal-title":"Blood"},{"key":"4","first-page":"513","article-title":"Allogeneic hematopoietic stem cell transplantation for chronic myeloid leukemia in Europe 2006: transplant activity, long-term data and current results. An analysis by the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT)","volume":"91","author":"Marrow","year":"2006","journal-title":"Haematologica"},{"key":"5","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1016\/j.bbmt.2009.03.013","article-title":"Late mortality and relapse following BuCy2 and HLA-identical sibling marrow transplantation for chronic myelogenous leukemia","volume":"15","author":"Kalaycio","year":"2009","journal-title":"Biol Blood Marrow Transplant"},{"key":"6","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/sj.leu.2402808","article-title":"Imatinib mesylate (STI571) in preparation for allogeneic hematopoietic stem cell transplantation and donor lymphocyte infusions in patients with Philadelphia-positive acute leukemias","volume":"17","author":"Nagler","year":"2003","journal-title":"Leukemia"},{"key":"7","article-title":"Use of tyrosine kinase inhibitors to prevent relapse after allogeneic hematopoietic stem cell transplantation for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: A position statement of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation","author":"Nagler","year":"2016","journal-title":"Cancer"},{"key":"8","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1182\/blood.V100.5.1590.h81702001590_1590_1595","article-title":"Imatinib mesylate therapy for relapse after allogeneic stem cell transplantation for chronic myelogenous leukemia","volume":"100","author":"Arlinghaus","year":"2002","journal-title":"Blood"},{"key":"9","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1038\/sj.leu.2403068","article-title":"Chronic Leukaemia Working Party of the European Group of B, Marrow T. Response to imatinib in patients who relapse after allogeneic stem cell transplantation for chronic myeloid leukemia","volume":"17","author":"Niederwieser","year":"2003","journal-title":"Leukemia"},{"key":"10","doi-asserted-by":"crossref","first-page":"5065","DOI":"10.1158\/1078-0432.CCR-03-0580","article-title":"Extended follow-up of patients treated with imatinib mesylate (gleevec) for chronic myelogenous leukemia relapse after allogeneic transplantation: durable cytogenetic remission and conversion to complete donor chimerism without graft-versus-host disease","volume":"10","author":"Soiffer","year":"2004","journal-title":"Clin Cancer Res"},{"key":"11","doi-asserted-by":"crossref","first-page":"7583","DOI":"10.1200\/JCO.2005.01.3110","article-title":"Sustained complete molecular remissions after treatment with imatinib-mesylate in patients with failure after allogeneic stem cell transplantation for chronic myelogenous leukemia: results of a prospective phase II open-label multicenter study","volume":"23","author":"Gschaidmeier","year":"2005","journal-title":"J Clin Oncol"},{"key":"12","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1038\/sj.bmt.1705554","article-title":"Imatinib therapy for chronic myeloid leukemia patients who relapse after allogeneic stem cell transplantation: a molecular analysis","volume":"39","author":"Baccarani","year":"2007","journal-title":"Bone Marrow Transplant"},{"key":"13","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.bbmt.2009.08.019","article-title":"Current status and perspectives of tyrosine kinase inhibitor treatment in the posttransplant period in patients with chronic myelogenous leukemia (CML)","volume":"16","author":"Bacher","year":"2010","journal-title":"Biol Blood Marrow Transplant"},{"key":"14","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1159\/000228587","article-title":"Second-generation tyrosine kinase inhibitors in the post-transplant period in patients with chronic myeloid leukemia or Philadelphia-positive acute lymphoblastic leukemia","volume":"122","author":"Bacher","year":"2009","journal-title":"Acta Haematol"},{"key":"15","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/j.bbmt.2009.11.026","article-title":"Response to tyrosine kinase inhibitor therapy in patients with chronic myelogenous leukemia relapsing in chronic and advanced phase following allogeneic hematopoietic stem cell transplantation","volume":"16","author":"Smith","year":"2010","journal-title":"Biol Blood Marrow Transplant"},{"key":"16","doi-asserted-by":"crossref","first-page":"4614","DOI":"10.1182\/blood-2007-04-082990","article-title":"Posttransplantation imatinib as a strategy to postpone the requirement for immunotherapy in patients undergoing reduced-intensity allografts for chronic myeloid leukemia","volume":"110","author":"Apperley","year":"2007","journal-title":"Blood"},{"key":"17","doi-asserted-by":"crossref","first-page":"2791","DOI":"10.1182\/blood-2006-04-019836","article-title":"Prophylactic administration of imatinib after hematopoietic cell transplantation for high-risk Philadelphia chromosome-positive leukemia","volume":"109","author":"Radich","year":"2007","journal-title":"Blood"},{"key":"18","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1182\/blood-2004-05-1746","article-title":"Early molecular response to posttransplantation imatinib determines outcome in MRD+ Philadelphia-positive acute lymphoblastic leukemia (Ph+ALL)","volume":"106","author":"Ledderose","year":"2005","journal-title":"Blood"},{"key":"19","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1038\/leu.2012.352","article-title":"Randomized comparison of prophylactic and minimal residual disease-triggered imatinib after allogeneic stem cell transplantation for BCR-ABL1-positive acute lymphoblastic leukemia","volume":"27","author":"Kiani","year":"2013","journal-title":"Leukemia"},{"key":"20","doi-asserted-by":"crossref","first-page":"87","DOI":"10.3324\/haematol.2009.011221","article-title":"Concurrent intensive chemotherapy and imatinib before and after stem cell transplantation in newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia. Final results of the CSTIBES02 trial","volume":"95","author":"Parody","year":"2010","journal-title":"Haematologica"},{"key":"21","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1182\/blood-2010-03-277152","article-title":"Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up results","volume":"117","author":"Kim","year":"2011","journal-title":"Blood"},{"key":"22","article-title":"Does Post-Transplant Maintenance Therapy With Tyrosine Kinase Inhibitors Improve Outcomes of Patients With High-Risk Philadelphia Chromosome-Positive Leukemia?","author":"Waller","year":"2016","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"23","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1002\/cncr.29141","article-title":"Phase 1\/2 study of nilotinib prophylaxis after allogeneic stem cell transplantation in patients with advanced chronic myeloid leukemia or Philadelphia chromosome-positive acute lymphoblastic leukemia","volume":"121","author":"Nagler","year":"2015","journal-title":"Cancer"},{"key":"24","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1634\/stemcells.2005-0069","article-title":"Effects of imatinib on normal hematopoiesis and immune activation","volume":"23","author":"Brossart","year":"2005","journal-title":"Stem Cells"},{"key":"25","first-page":"1","article-title":"Immune reconstitution post allogeneic transplant and the impact of immune recovery on the risk of infection","author":"Rezvani","year":"2016","journal-title":"Virulence"},{"key":"26","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1038\/sj.bmt.1703056","article-title":"Immune reconstitution assessed during five years after allogeneic bone marrow transplantation","volume":"27","author":"Ishigatsubo","year":"2001","journal-title":"Bone Marrow Transplant"},{"key":"27","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.exphem.2010.09.005","article-title":"Poor cytokine-induced phosphorylation in chronic myeloid leukemia patients at diagnosis is effectively reversed by tyrosine kinase inhibitor therapy","volume":"39","author":"Mustjoki","year":"2011","journal-title":"Exp Hematol"},{"key":"28","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/s11046-009-9181-0","article-title":"Immune deficits in allogeneic hematopoietic stem cell transplant (HSCT) recipients","volume":"168","author":"Battiwalla","year":"2009","journal-title":"Mycopathologia"},{"key":"29","doi-asserted-by":"crossref","first-page":"2107","DOI":"10.1111\/j.1582-4934.2008.00234.x","article-title":"Nilotinib hampers the proliferation and function of CD8+ T lymphocytes through inhibition of T cell receptor signalling","volume":"12","author":"Guillaume","year":"2008","journal-title":"J Cell Mol Med"},{"key":"30","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1002\/ijc.25233","article-title":"The BCR\/ABL-inhibitors imatinib, nilotinib and dasatinib differentially affect NK cell reactivity","volume":"127","author":"Krusch","year":"2010","journal-title":"Int J Cancer"},{"key":"31","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1182\/blood-2012-11-465039","article-title":"Tyrosine kinase inhibitors impair B-cell immune responses in CML through off-target inhibition of kinases important for cell signaling","volume":"122","author":"Chaidos","year":"2013","journal-title":"Blood"},{"key":"32","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/leu.2011.239","article-title":"NK cells are dysfunctional in human chronic myelogenous leukemia before and on imatinib treatment and in BCR-ABL-positive mice","volume":"26","author":"Rossig","year":"2012","journal-title":"Leukemia"},{"key":"33","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1016\/j.bbmt.2011.08.011","article-title":"Long-term follow-up of allogeneic hematopoietic stem cell transplantation for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: impact of tyrosine kinase inhibitors on treatment outcomes","volume":"18","author":"Thomas","year":"2012","journal-title":"Biol Blood Marrow Transplant"},{"key":"34","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1038\/sj.leu.2403401","article-title":"Imatinib inhibits the activation and proliferation of normal T lymphocytes","volume":"18","author":"Dazzi","year":"2004","journal-title":"Leukemia"},{"key":"35","doi-asserted-by":"crossref","first-page":"3406","DOI":"10.1182\/blood-2006-04-018705","article-title":"Imatinib mesylate selectively impairs expansion of memory cytotoxic T cells without affecting the control of primary viral infections","volume":"108","author":"Ochsenbein","year":"2006","journal-title":"Blood"},{"key":"36","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1182\/blood-2004-07-2527","article-title":"Imatinib inhibits T-cell receptor-mediated T-cell proliferation and activation in a dose-dependent manner","volume":"105","author":"Wiestner","year":"2005","journal-title":"Blood"},{"key":"37","doi-asserted-by":"crossref","first-page":"6955","DOI":"10.4049\/jimmunol.181.10.6955","article-title":"Imatinib mesylate inhibits CD4+ CD25+ regulatory T cell activity and enhances active immunotherapy against BCR-ABL- tumors","volume":"181","author":"Katsanis","year":"2008","journal-title":"J Immunol"},{"key":"38","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1038\/nm.2438","article-title":"Imatinib potentiates antitumor T cell responses in gastrointestinal stromal tumor through the inhibition of Ido","volume":"17","author":"Antonescu","year":"2011","journal-title":"Nat Med"},{"key":"39","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1111\/j.1582-4934.2009.00500_1.x","article-title":"Nilotinib inhibits the Src-family kinase LCK and T-cell function","volume":"13","author":"Hughes","year":"2009","journal-title":"J Cell Mol Med"},{"key":"40","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1016\/j.exphem.2008.05.002","article-title":"Dasatinib exerts an immunosuppressive effect on CD8+ T cells specific for viral and leukemia antigens","volume":"36","author":"Schmitt","year":"2008","journal-title":"Exp Hematol"},{"key":"41","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.exphem.2008.09.013","article-title":"Dasatinib inhibits recombinant viral antigen-specific murine CD4+ and CD8+ T-cell responses and NK-cell cytolytic activityand","volume":"37","author":"Hayball","year":"2009","journal-title":"Exp Hematol"},{"key":"42","doi-asserted-by":"crossref","first-page":"2484","DOI":"10.1158\/1078-0432.CCR-07-4393","article-title":"Profound inhibition of antigen-specific T-cell effector functions by dasatinib","volume":"14","author":"Seggewiss","year":"2008","journal-title":"Clin Cancer Res"},{"key":"43","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1038\/leu.2011.135","article-title":"Expansion of highly differentiated CD8+ T-cells or NK-cells in patients treated with dasatinib is associated with cytomegalovirus reactivation","volume":"25","author":"Seggewiss","year":"2011","journal-title":"Leukemia"},{"key":"44","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/sj.bmt.1705584","article-title":"Immune recovery in children undergoing allogeneic stem cell transplantation: absolute CD8+ CD3+ count reconstitution is associated with survival","volume":"39","author":"Schwabe","year":"2007","journal-title":"Bone Marrow Transplant"},{"key":"45","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1111\/j.1365-2141.2004.04891.x","article-title":"Clinical impact of early absolute lymphocyte count after allogeneic stem cell transplantation","volume":"125","author":"Lee","year":"2004","journal-title":"Br J Haematol"},{"key":"46","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1038\/sj.bmt.1701889","article-title":"Quantitative lymphocyte subset reconstitution after allogeneic hematopoietic transplantation from matched related donors with CD34+ selected PBPC grafts unselected PBPC grafts or BM grafts","volume":"24","author":"Finke","year":"1999","journal-title":"Bone Marrow Transplant"},{"key":"47","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1046\/j.1365-2141.2002.03560.x","article-title":"Immune reconstitution after haematopoietic cell transplantation in children: immunophenotype analysis with regard to factors affecting the speed of recovery","volume":"118","author":"Chybicka","year":"2002","journal-title":"Br J Haematol"},{"key":"48","doi-asserted-by":"crossref","first-page":"e30494","DOI":"10.1371\/journal.pone.0030494","article-title":"The kinetics of early T, B cell immune recovery after bone marrow transplantation in RAG-2-deficient SCID patients","volume":"7","author":"Somech","year":"2012","journal-title":"PLoS One"},{"key":"49","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.bcmd.2016.03.001","article-title":"Assessment of immune reconstitution status in recipients of a successful hematopoietic stem cell transplant from peripheral blood after reduced intensity conditioning","volume":"58","author":"Gomez-Almaguer","year":"2016","journal-title":"Blood Cells Mol Dis"},{"key":"50","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1007\/s00281-008-0132-5","article-title":"Reconstitution of the immune system after hematopoietic stem cell transplantation in humans","volume":"30","author":"Roosnek","year":"2008","journal-title":"Semin Immunopathol"},{"key":"51","doi-asserted-by":"crossref","first-page":"3239","DOI":"10.1182\/blood.V79.12.3239.bloodjournal79123239","article-title":"CD16- CD56+ natural killer cells after bone marrow transplantation","volume":"79","author":"Schmidt","year":"1992","journal-title":"Blood"},{"key":"52","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1016\/j.bbmt.2009.05.015","article-title":"Lymphocyte recovery is a major determinant of outcome after matched unrelated myeloablative transplantation for myelogenous malignancies","volume":"15","author":"Remberger","year":"2009","journal-title":"Biol Blood Marrow Transplant"},{"key":"53","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1038\/nri3212","article-title":"Advances in graft-versus-host disease biology and therapy","volume":"12","author":"Abedi","year":"2012","journal-title":"Nat Rev Immunol"},{"key":"54","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1182\/blood-2014-01-514752","article-title":"Current issues in chronic graft-versus-host disease","volume":"124","author":"Ritz","year":"2014","journal-title":"Blood"},{"key":"55","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1182\/blood.V59.6.1292.1292","article-title":"T-cell subpopulations identified by monoclonal antibodies after human marrow transplantation. I. Helper-inducer and cytotoxic-suppressor subsets","volume":"59","author":"Thomas","year":"1982","journal-title":"Blood"},{"key":"56","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1182\/blood-2015-10-672345","article-title":"Unbalanced recovery of regulatory and effector T cells after allogeneic stem cell transplantation contributes to chronic GVHD","volume":"127","author":"Antin","year":"2016","journal-title":"Blood"},{"key":"57","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1080\/146532402320776026","article-title":"B-cell immunity after allogeneic hematopoietic cell transplantation","volume":"4","author":"Storek","year":"2002","journal-title":"Cytotherapy"},{"key":"58","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1111\/j.1399-0039.2011.01820.x","article-title":"Thymus and immune reconstitution after allogeneic hematopoietic stem cell transplantation in humans: never say never again","volume":"79","author":"Clave","year":"2012","journal-title":"Tissue Antigens"},{"key":"59","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1182\/blood.V94.1.333.413a31_333_339","article-title":"Role of natural killer cell alloreactivity in HLA-mismatched hematopoietic stem cell transplantation","volume":"94","author":"Velardi","year":"1999","journal-title":"Blood"},{"key":"60","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1172\/JCI200522492","article-title":"Age-dependent incidence, time course, and consequences of thymic renewal in adults","volume":"115","author":"Gress","year":"2005","journal-title":"J Clin Invest"},{"key":"61","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1186\/1479-5876-11-188","article-title":"Utilization of TREC and KREC quantification for the monitoring of early T- and B-cell neogenesis in adult patients after allogeneic hematopoietic stem cell transplantation","volume":"11","author":"Na","year":"2013","journal-title":"J Transl Med"},{"key":"62","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.1182\/blood.V100.6.2235","article-title":"Direct evidence for new T-cell generation by patients after either T-cell-depleted or unmodified allogeneic hematopoietic stem cell transplantations","volume":"100","author":"Young","year":"2002","journal-title":"Blood"},{"key":"63","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1182\/blood.V98.4.1116","article-title":"Quantitation of T-cell neogenesisafter allogeneic bone marrow transplantation in adults","volume":"98","author":"Ritz","year":"2001","journal-title":"Blood"},{"key":"64","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1182\/blood.V110.11.2815.2815","article-title":"Kinase domain mutations of BCR-ABL frequently precede imatinib-based therapy and give rise to relapse in patients with de novo Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL)","volume":"110","author":"Ottmann","year":"2007","journal-title":"Blood"},{"key":"65","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/j.leukres.2014.02.005","article-title":"Use of a high sensitive nanofluidic array for the detection of rare copies of BCR-ABL1 transcript in patients with Philadelphia-positive acute lymphoblastic leukemia in complete response","volume":"38","author":"Soverini","year":"2014","journal-title":"Leuk Res"}],"container-title":["Oncotarget"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.13439","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,10]],"date-time":"2020-05-10T13:20:47Z","timestamp":1589116847000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.13439"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,11,18]]},"references-count":65,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,1,3]]}},"alternative-id":["13439","27880933"],"URL":"https:\/\/doi.org\/10.18632\/oncotarget.13439","relation":{},"ISSN":["1949-2553"],"issn-type":[{"value":"1949-2553","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,11,18]]}}}